Nathanael R. Fillmore
Publications / 2024
paper
Journal of the American Academy of Dermatology2024doi:10.1016/j.jaad.2023.10.051

Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma.

Daniel Y. Kim, Susan M. Swetter, Linden Huhmann, Matthew P. Dizon, Jacqueline M. Ferguson, Thomas F. Osborne, Allyson C. Spence, Amina Ziad, Nathanael Fillmore‡, Rebecca I. Hartman‡

‡ Equal senior authorship

Summary

Anti-PD-1 monotherapy demonstrated the highest melanoma-specific survival rates among veteran patients in both adjuvant and systemic treatment settings. These results confirm that immunotherapy is effective for this high-risk population, who often have more comorbidities and different clinical profiles than participants in standard clinical trials.

Key result

Among veteran patients with cutaneous melanoma in the systemic setting, BRAF/MEK inhibitors (adjusted hazard ratio, 2.61; 95% CI, 1.74-3.90) and anti-CTLA-4 monotherapy (adjusted hazard ratio, 1.87; 95% CI, 1.15-3.02) were associated with significantly higher melanoma-specific mortality compared with anti-PD-1 monotherapy.

Key figure

Key figure from Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma.